These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10932610)

  • 1. Concerning to low molecular weight heparins (LMWHs) in acut coronary syndromes.
    Borja J; Olivella P
    S D J Med; 2000 Jul; 53(7):277-9. PubMed ID: 10932610
    [No Abstract]   [Full Text] [Related]  

  • 2. Low molecular weight heparins in acute coronary syndrome.
    Creekmore F
    S D J Med; 2000 Jan; 53(1):21-3. PubMed ID: 10652862
    [No Abstract]   [Full Text] [Related]  

  • 3. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotics and anticoagulants in coronary syndromes and stroke.
    Turpie AG
    Semin Thromb Hemost; 2000; 26 Suppl 1():79-83. PubMed ID: 11011811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
    Lindahl B; Venge P; Wallentin L
    J Am Coll Cardiol; 1997 Jan; 29(1):43-8. PubMed ID: 8996293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-fractionated heparin versus low molecular weight heparin in acute coronary syndromes].
    González Pacheco H
    Arch Cardiol Mex; 2001; 71 Suppl 1():S63-8. PubMed ID: 11565348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dynamics of lipid peroxidation and antioxidant defense in response to dalteparin therapy in acute coronary syndrome].
    Tarasov NI; Terent'eva NV; Vorontsova NL; Barbarash LS
    Klin Med (Mosk); 2004; 82(3):63-6. PubMed ID: 15114779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight heparins in the treatment of unstable angina.
    Ageno W; Turpie AG
    Minerva Cardioangiol; 2002 Dec; 50(6):643-51. PubMed ID: 12473984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia--a randomised placebo-controlled double blind multicentre trial.
    Jivegård L; Drott C; Gelin J; Groth O; Hensäter M; Jensen N; Johansson G; Konrad P; Lindberg B; Lindhagen A; Lundqvist B; Oden A; Smith L; Stenberg B; Thornell E; Wingren U; Ortenwall P
    Eur J Vasc Endovasc Surg; 2005 Feb; 29(2):190-8. PubMed ID: 15649728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low-molecular heparins in the treatment of non-ST elevation acute coronary syndrome].
    Komarov AL; Panchenko EP
    Ter Arkh; 2004; 76(12):93-6. PubMed ID: 15724939
    [No Abstract]   [Full Text] [Related]  

  • 13. Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
    Mälarstig A; Lindahl B; Wallentin L; Siegbahn A
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1667-73. PubMed ID: 16627810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dalteparin as the primary low-molecular-weight heparin on a hospital formulary.
    Goldman MC
    Conn Med; 2009 Jan; 73(1):23-8. PubMed ID: 19248570
    [No Abstract]   [Full Text] [Related]  

  • 15. [Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
    Dudek D; Chyrchel M; Legutko J; Bartuś S; Rzeszutko L; Dubiel JS
    Przegl Lek; 2004; 61(12):1301-4. PubMed ID: 15850317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparins: are they different?
    Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM
    Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of amyloidosis using low-molecular-weight heparins.
    Zhu H; Yu J; Kindy MS
    Mol Med; 2001 Aug; 7(8):517-22. PubMed ID: 11591887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular weight heparins.
    Talley JD
    J Ark Med Soc; 1997 Apr; 93(11):555-6. PubMed ID: 9114648
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
    Turpie AG
    Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.
    Rubboli A; Ottani F; Capecchi A; Brancaleoni R; Galvani M; Swahn E
    Cardiology; 2007; 107(2):132-9. PubMed ID: 16864962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.